AU2018269403B2 - Pharmaceutical agents, compositions, and methods relating thereto - Google Patents

Pharmaceutical agents, compositions, and methods relating thereto Download PDF

Info

Publication number
AU2018269403B2
AU2018269403B2 AU2018269403A AU2018269403A AU2018269403B2 AU 2018269403 B2 AU2018269403 B2 AU 2018269403B2 AU 2018269403 A AU2018269403 A AU 2018269403A AU 2018269403 A AU2018269403 A AU 2018269403A AU 2018269403 B2 AU2018269403 B2 AU 2018269403B2
Authority
AU
Australia
Prior art keywords
compound
insulin
cells
glucose
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269403A
Other languages
English (en)
Other versions
AU2018269403A1 (en
Inventor
Zi-Jian LAN
Ronan Power
Thirupathi Reddy Yerramreddy
Alexandros Yiannikouris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Publication of AU2018269403A1 publication Critical patent/AU2018269403A1/en
Application granted granted Critical
Publication of AU2018269403B2 publication Critical patent/AU2018269403B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2018269403A 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto Active AU2018269403B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508730P 2017-05-19 2017-05-19
US62/508,730 2017-05-19
PCT/US2018/030371 WO2018212980A1 (en) 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto

Publications (2)

Publication Number Publication Date
AU2018269403A1 AU2018269403A1 (en) 2019-11-14
AU2018269403B2 true AU2018269403B2 (en) 2025-03-27

Family

ID=64274560

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018269403A Active AU2018269403B2 (en) 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto

Country Status (10)

Country Link
US (2) US11014954B2 (enExample)
EP (1) EP3624809A4 (enExample)
JP (1) JP7224303B2 (enExample)
CN (2) CN120647702A (enExample)
AU (1) AU2018269403B2 (enExample)
CA (1) CA3061893A1 (enExample)
RU (1) RU2765286C2 (enExample)
SA (1) SA519410561B1 (enExample)
SG (1) SG11201909932YA (enExample)
WO (1) WO2018212980A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055016A1 (en) * 2001-03-22 2003-03-20 Zhen Huang Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
US20090137520A1 (en) * 2005-10-13 2009-05-28 Elfatih Elzein A1 adenosine receptor agonists
EP3144001A1 (en) * 2015-09-15 2017-03-22 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
WO2017048253A1 (en) * 2014-03-14 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
EP2192905A4 (en) 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
CN105377271A (zh) 2013-03-15 2016-03-02 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055016A1 (en) * 2001-03-22 2003-03-20 Zhen Huang Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
US20090137520A1 (en) * 2005-10-13 2009-05-28 Elfatih Elzein A1 adenosine receptor agonists
WO2017048253A1 (en) * 2014-03-14 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
EP3144001A1 (en) * 2015-09-15 2017-03-22 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof

Also Published As

Publication number Publication date
RU2765286C2 (ru) 2022-01-28
NZ758538A (en) 2025-08-29
JP7224303B2 (ja) 2023-02-17
WO2018212980A1 (en) 2018-11-22
CN110545822A (zh) 2019-12-06
EP3624809A1 (en) 2020-03-25
US11613552B2 (en) 2023-03-28
BR112019022918A2 (pt) 2020-05-26
CN120647702A (zh) 2025-09-16
RU2019134865A (ru) 2021-06-21
RU2019134865A3 (enExample) 2021-06-30
EP3624809A4 (en) 2021-03-03
US11014954B2 (en) 2021-05-25
JP2020520904A (ja) 2020-07-16
SA519410561B1 (ar) 2024-03-06
US20210238216A1 (en) 2021-08-05
US20200123191A1 (en) 2020-04-23
CA3061893A1 (en) 2018-11-22
AU2018269403A1 (en) 2019-11-14
SG11201909932YA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
AU2016222315B2 (en) Compositions of selenoorganic compounds and methods of use thereof
JP7637050B2 (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ－アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
EP3334429B1 (en) Hyperphenylalaninemia and treatments thereof
TW201018463A (en) Compounds, compositions and methods of using same for modulating uric acid levels
US6521645B2 (en) Methods for the treatment and prevention of urinary stone disease
US9150505B2 (en) Prophylactic or therapeutic agent for diabetes or obesity
KR20100080561A (ko) 5-리폭시게나아제 활성화 단백질(ｆｌａｐ) 억제제
CN112638866A (zh) 索拉非尼衍生物的共晶体及其制备方法
US11613552B2 (en) Pharmaceutical agents, compositions, and methods relating thereto
EP4615462A1 (en) Methods and compositions for treating wolfram syndrome
HK40017181A (en) Pharmaceutical agents, compositions, and methods relating thereto
CN110799518B (zh) 钴胺素衍生物及其用于治疗因缺乏维生素b12供应引起的疾病的用途
BR112019022918B1 (pt) Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos
EP4487698A1 (en) A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human
EP3144001B1 (en) Compositions of selenoorganic compounds and methods of use thereof
JP2021524853A (ja) ハンチントン病を治療するのに使用するための薬学的化合物
US20230346765A1 (en) Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof
EP4079306A1 (en) Therapeutic agent containing fused pyrimidine compound as active ingredient
US10399946B2 (en) Solid forms of an S-Nitrosoglutathione reductase inhibitor
TW202233173A (zh) 包括１５－ＨＥＴｒＥ之醫藥組合物及其使用方法
CN118059102A (zh) 一种延缓衰老的药物
HK40067960A (en) Therapeutic or prophylactic method for diabetes using combination medicine

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 01 MAY 2023 TO 01 DEC 2023 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 01 DEC 2023

FGA Letters patent sealed or granted (standard patent)